Company intelligence / Profile preview
Shanghai Humantech Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Humantech Biotechnology is advancing a pipeline focused on immunotherapies—primarily autologous dendritic cell vaccines—for oncology indications. Its lead asset, a recombinant EGF–CRM197 therapeutic cancer vaccine, has reached Phase 2 in non-small cell lung cancer. The company’s "Prodencel" product—a dendritic cell-based tumor vaccine—is in Phase 1 clinical trials for metastatic castration-resistant prostate cancer as of late 2022/early 2023. No published pivotal efficacy results yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Dendritic cell vaccineTherapeutic vaccineBiological productsCell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Humantech Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Humantech Biotechnology.